| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | AIO; IKZF3; ZNFN1A3;;IKZF3 |
| WB Predicted band size | Calculated MW: 58 kDa ; Observed MW: 65 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human IKZF3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于IKZF3抗体的3篇参考文献示例(注：以下内容为示例性概括，具体文献需通过学术数据库核实)：
---
1. **标题**：*IKZF3 as a Novel Therapeutic Target in B-Cell Malignancies*
**作者**：Smith A, et al.
**摘要**：研究探讨了IKZF3在B细胞恶性肿瘤中的功能，发现其抗体靶向治疗可抑制肿瘤细胞增殖并诱导凋亡，为开发单克隆抗体疗法提供实验依据。
2. **标题**：*Autoantibody Profiling Identifies IKZF3 as a Biomarker in Autoimmune Disorders*
**作者**：Chen L, et al.
**摘要**：通过自身抗体筛选，发现IKZF3抗体在系统性红斑狼疮(SLE)患者血清中显著升高，提示其可能参与自身免疫病理过程并作为潜在诊断标志物。
3. **标题**：*CRISPR-Based Screening Reveals IKZF3 Dependency in Multiple Myeloma Drug Resistance*
**作者**：Wang Y, et al.
**摘要**：利用CRISPR筛选技术，证实IKZF3缺失增强多发性骨髓瘤对蛋白酶体抑制剂的敏感性，抗IKZF3抗体联合治疗可逆转耐药性。
---
建议通过PubMed或Google Scholar搜索关键词“IKZF3 antibody therapeutic”或“IKZF3 autoantibody”获取具体文献。如需进一步协助定位论文，请告知!
IKZF3 (Ikaros Family Zinc Finger 3), also known as Aiolos, is a transcription factor belonging to the Ikaros family of proteins. It plays a critical role in regulating lymphocyte development, differentiation, and immune response. Structurally, it contains zinc finger domains that enable DNA binding and interaction with other proteins, including its family member IKZF1 (Ikaros). IKZF3 is predominantly expressed in hematopoietic cells, particularly B cells, T cells, and plasma cells, where it modulates gene expression involved in cell signaling, proliferation, and apoptosis.
Antibodies targeting IKZF3 are valuable tools in research and diagnostics. They help detect IKZF3 protein expression in cells or tissues, aiding studies on its functional roles in immunity and disease. Dysregulation of IKZF3 has been implicated in autoimmune disorders, such as systemic lupus erythematosus (SLE), and hematologic malignancies, including multiple myeloma and B-cell lymphomas. For example, reduced IKZF3 expression in regulatory T cells (Tregs) may impair immune tolerance, while aberrant activity in B cells can drive pathological antibody production.
Clinically, IKZF3 antibodies are explored for therapeutic applications. Inhibiting IKZF3 in cancers may synergize with existing therapies, such as immunomodulatory drugs (IMiDs), which target related pathways. However, challenges remain in balancing therapeutic efficacy with potential immunosuppressive side effects. Research continues to elucidate IKZF3's precise mechanisms and optimize antibody-based strategies for precision medicine.
×
